**Cellular Therapy & Immunobiology Working Party**

**Chair:** Christian Chabannon  
**Secretary:** Annalisa Ruggeri

**Subcommittee Leaders:**  
- Immune Modulation: Francesco Dazzi, Florent Malard  
- Immune Monitoring: Luca Vago  
- HLA/Immunogenetics: Katharina Fleischhauer  
- Liaison with the Industry and EU bodies: Jürgen Kubal

**HSC based therapies / Eurocord:** Franco Locatelli, Annalisa Ruggeri  
**Immune Effector Cells therapies:** Alvaro Urbano, Michael Hudecek  
**Solid tumours:** Paolo Pedrazzoli, Ulrike Köhl  
**Nurses Group rep.:** Rose Ellard

---

**CTIWP Mission**

**Mission**
To understand and exploit the biological and immunological events occurring upon HSCT at large, and to implement modern cellular therapies based on cellular and gene engineering approaches to improve transplantation outcomes.

The CTIWP aims at fostering cellular therapy in Europe, through a continuous crosstalk between basic science findings, transplant immunobiology observations and implementation of cell therapy approaches to answer unmet medical needs.

**Education early 2020**

2nd European CAR T Cell Meeting was organized in Sitges (Spain) with high level of attendees.

---

**Cellular Therapy Registry**

The Cell Therapy Registry (CTR) aims to collect data on stem cells, progenitors or mature cells, such as T-lymphocytes, unmanipulated, such as DLI, or sorted and/or cultured and/or genetically manipulated, such as CAR T-cells, used for treatment in combination with HSCT or alone, and including advanced therapeutic medicinal products (ATMP), as well as data on the clinical characteristics and outcomes of the patients.

**PLEASE CONTRIBUTE... AND REPORT YOUR PATIENTS**

**Ongoing studies**

Currently ongoing retrospective studies include:

- Impact of COVID-19 on the delivery of CAR T-cell therapy (S. Ghorashian)  
- DLI in Haplo PT Cy (N. Santoro)  
- MSCs for treatment of steroid-resistant acute GVHD (A. Galleu)  
- Evaluation of KIR-HLA class I Ligand models for donor selection (J. Schetelig)  
- + 4 new studies starting soon

**Completed studies / data being analysed**

- Donor-recipient HLA matching for UD HSCT outcomes (A. Ruggeri, K. Fleischhauer)  
- Identifying CARs centers and CAR activity in Europe (A. Urbano)  
- Retrospective study on TX in adult soft tissue sarcoma (C.E. Heilig)  
- Long-term survival in patients with metastatic breast cancer receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation (M. Martino)

---

**CTIWP sessions**

**Monday August 31st**  
**Cell Therapy Day, 09:30-17:50**

**Jon J. van Rood Award, 18:00-18:30, Auditorium 1**

The prestigious Jon van Rood Award will be awarded to Cristina Toffalori, for her paper: Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

**CTIWP presentations originally accepted at @ EBMT 2020**

**Presentations**

- Donor-recipient HLA matching for UD HSCT outcomes (A. Ruggeri)  
- DLI after haploidentical HSCT with PT Cy: a study on behalf of the CTIWP (N. Santoro)  
- Optimizing outcomes of acute leukemia after transplants with single unrelated cord blood units selected according to current international recommendations for cell dose and HLA match (H Rafii)  
- An update of the EBMT survey on CAR T-cell activity in Europe. On behalf of the CTIWP (A. Urbano)

**E-Poster Stem cell source area**

Reduced intensity versus myeloablative conditioning in cord blood transplantation for AML (40-60 years) across highly mismatched HLA barriers - Analysis by CTIWP/Eurocord of EBMT (V. Sheth)

---

**Key Publications 2019**

- Development of adaptive immune effector therapies in solid tumors  
  Haematologica. 2019 Dec;104(12):e543  

- Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the ALWP and the Cord Blood Committee of the CTIWP of the EBMT  
  Bone Marrow Transplant. 2019 Feb 6. doi: 10.1038/s41409-018-0263-4

- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell ALL-an expert opinion from the EBMT and ASBMT  
  Bone Marrow Transplant. 2019 Nov;54(11):1868. doi: 10.1038/s41409-019-0451-2

- The CTIWP activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies  
  Bone Marrow Transplant. 2019 Feb 6. doi: 10.1038/s41409-018-0260-9

- Beneficial role of CD4+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukemias: results from a clinicobiological EBMT registry study mostly in the T-cell-depleted setting  
  Bone Marrow Transplant. 2019 Jul;54(1):98-106. doi: 10.1038/s41409-019-0281-x

- CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives  

- Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease  

---

**Upcoming events**

**February 4-6, 2021:** The 3rd EBMT - EHA European CAR-T Cell Meeting  
**Planned for early 2021:** The 3rd CTIWP Scientific Symposium

---

**Contact CTIWP**

For participation in or information on CTIWP studies, or if you are interested in submitting a proposal, please contact: CTIWEBMT@lumc.nl

---

**www.ebmt.org #EBMT20Virtual**